Oruka Therapeutics, Inc. Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One
Oruka Therapeutics, Inc. (ORKA) had Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One of $3.05 million as of 2017-12-31, per its 10-K filed 2018-03-22.
Discontinued › Notes › Available-for-Sale Securities, Debt Maturities
us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue · last filed 2018-03-22
- 2017-12-31: Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One $3.05M.
- 2017-09-30: Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One $7.81M.
- 2017-06-30: Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One $6.91M.
- 2017-03-31: Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One $13.04M.
| Period end | Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One |
|---|---|
| 2017-12-31 | $3.05M 10-K · filed 2018-03-22 |
| 2017-09-30 | $7.81M 10-Q · filed 2017-11-09 |
| 2017-06-30 | $6.91M 10-Q · filed 2017-08-03 |
| 2017-03-31 | $13.04M 10-Q · filed 2017-05-15 |
| 2016-12-31 | $13.76M 10-K · filed 2017-03-21 |
| 2016-09-30 | $15.37M 10-Q · filed 2016-11-14 |
| 2016-06-30 | $11.98M 10-Q · filed 2016-08-09 |
| 2016-03-31 | $910.00K 10-Q · filed 2016-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Veradermics, Inc (MANE) | United States | $4.839B |